Minerva Neurosciences Inc (NERV)
NASDAQ: NERVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NERV stock chart
Technical analysisKey statistics
All statistics- Market cap
- $99.67M
- EPS (TTM)
- -$33.83
- Dividend yield
- None
- 52-week range
- 1.96 – 8.80
- Day range
- 1.99 – 2.12
- Volume / Avg
- 137.66K / 164.71K
- Beta
- —
- Shares outstanding
- 49.84M
52-week range
NERV stock today
Minerva Neurosciences (NERV) closed at $2.00 on Nov 20, down 5.66% (-$0.12), versus the S&P 500's 3.70% decline. Shares are 77.3% below their 52-week high of $8.80, set on Mar 16, 2026 and 2.0% above the 52-week low of $1.96, near the bottom of the past year's range. NERV is down 50.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 49.2%.
Minerva Neurosciences has posted a net loss over the last twelve months (EPS of -$33.83), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Minerva Neurosciences
Company profileMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Remy Luthringer Ph.D.
- Headquarters
- Burlington, MA
- Employees
- 7
- IPO year
- 2014
- Website
- minervaneurosciences.com
Financial highlights
Full financialsMinerva Neurosciences reported a net loss of $293.4 million, compared with net income of $1.4 million a year earlier. Diluted earnings per share came in at -$34.67, down from $0.19.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $0 |
| Growth | — | — | — | — | -100.00% |
| Net income | $-293.42M | $1.44M | $-30.01M | $-32.11M | $-49.91M |
| EPS (diluted) | $-34.67 | $0.19 | $-4.61 | $-6.01 | $-9.35 |
Analyst forecast
ForecastConsensus (3 analysts)
buy
Avg. price target
$10.33+416.50%
- Strong buy 1
- Buy 1
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 6, 2026
- EPS actual vs est.
- $-1.60 vs $-0.14
- Surprise
- -1042.86%
NERV news
All NERV news- Minerva Neurosciences, Inc. Revises November 12, 2026 KOL Event Transcript to Clarify Regulatory StatementsNasdaq
- Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business UpdatesGlobeNewswire
- Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in LondonGlobeNewswire
Minerva Neurosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ORGOOrganogenesis Holdings Inc. Class A | 0.7716 | -2.23% | $100.16M | vs NERV |
| CNTNCanton Strategic Holdings Inc. | 1.21 | -1.63% | $98.78M | vs NERV |
| UNCYUnicycive Therapeutics Inc. | 3.35 | -5.10% | $97.77M | vs NERV |
| NBPNovaBridge Biosciences ADR | 0.83 | -5.66% | $96.28M | vs NERV |
| FHTXFoghorn Therapeutics Inc. | 1.72 | -3.37% | $103.14M | vs NERV |
| GNLXGenelux Corporation | 2.17 | -4.82% | $103.36M | vs NERV |
| PDSBPDS Biotechnology Corporation | 0.7774 | -3.70% | $95.39M | vs NERV |
| NRXPNRX Pharmaceuticals Inc. | 2.15 | -15.69% | $95.31M | vs NERV |
Indexes, lists and sector
Minerva Neurosciences stock FAQ
What is Minerva Neurosciences's stock price today?
NERV last traded at $2.00 as of Nov 20, 4:00 PM EST, down 5.66% on the day. Prices are delayed at least 15 minutes.
Does Minerva Neurosciences pay a dividend?
No. Minerva Neurosciences does not currently pay a regular cash dividend.
Who is Minerva Neurosciences's CEO?
Dr. Remy Luthringer Ph.D. is the chief executive officer of Minerva Neurosciences Inc, which has about 7 employees.
Has NERV ever split its stock?
Yes. The most recent NERV stock split was a 1-for-8 split on Jun 21, 2022.
What is the NERV 52-week high?
The 52-week high for NERV is $8.80 and the 52-week low is $1.96. The stock is currently 77.3% below its high.